A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
Status:
Withdrawn
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, Phase II study of BBI503 administered to adult patients
with selected advanced urologic malignancies. The primary objective of this study is to
evaluate the disease control rate of patients with renal cell cancer and urothelial carcinoma
treated with BBI503.
Phase:
Phase 2
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc